Insider Selling: Phibro Animal Health (NASDAQ:PAHC) CEO Sells $384,665.60 in Stock

Posted by Defense World Staff on Apr 19th, 2026

Phibro Animal Health Corporation (NASDAQ:PAHC – Get Free Report) CEO Jack Bendheim sold 7,040 shares of Phibro Animal Health stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $54.64, for a total value of $384,665.60. Following the sale, the chief executive officer directly owned 117,000 shares in the company, valued at $6,392,880. The trade was a 5.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jack Bendheim also recently made the following trade(s):

On Tuesday, April 14th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $59.08, for a total value of $415,923.20.
On Thursday, March 19th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.52, for a total value of $369,740.80.
On Wednesday, March 18th, Jack Bendheim sold 10,560 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.68, for a total value of $556,300.80.
On Tuesday, March 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.66, for a total value of $272,764.80.
On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.91, for a total value of $258,244.80.
On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $53.73, for a total value of $378,259.20.
On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.37, for a total value of $361,644.80.
On Friday, February 20th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.42, for a total value of $361,996.80.
On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.40, for a total value of $361,856.00.
On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.96, for a total value of $365,798.40.

Phibro Animal Health Stock Performance

Shares of PAHC stock opened at $57.07 on Friday. The business’s 50-day moving average price is $53.37 and its 200-day moving average price is $45.11. Phibro Animal Health Corporation has a 12 month low of $16.16 and a 12 month high of $60.08. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of 25.36, a PEG ratio of 0.83 and a beta of 0.69. The company has a current ratio of 3.05, a quick ratio of 1.22 and a debt-to-equity ratio of 2.14.

Phibro Animal Health (NASDAQ:PAHC – Get Free Report) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.18. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The firm had revenue of $373.91 million for the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Equities research analysts forecast that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th were paid a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend was Wednesday, March 4th. Phibro Animal Health’s payout ratio is currently 21.33%.

Hedge Funds Weigh In On Phibro Animal Health

Several institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in Phibro Animal Health by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 1,539,593 shares of the company’s stock valued at $57,519,000 after buying an additional 13,884 shares during the period. State Street Corp lifted its stake in Phibro Animal Health by 5.4% in the fourth quarter. State Street Corp now owns 942,279 shares of the company’s stock valued at $35,204,000 after buying an additional 48,243 shares during the period. Millennium Management LLC lifted its stake in Phibro Animal Health by 4,227.1% in the fourth quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock valued at $23,959,000 after buying an additional 626,492 shares during the period. Geode Capital Management LLC lifted its stake in Phibro Animal Health by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 569,111 shares of the company’s stock valued at $21,265,000 after buying an additional 21,951 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in Phibro Animal Health by 1.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 492,335 shares of the company’s stock valued at $18,394,000 after buying an additional 6,826 shares during the period. 99.34% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Phibro Animal Health

Here are the key news stories impacting Phibro Animal Health this week:

Positive Sentiment: Recent quarterly results and FY‑2026 guidance support the rally — Phibro beat EPS and revenue expectations and set FY‑2026 EPS guidance of roughly 2.93–3.10, helping justify the higher share price. MarketBeat PAHC coverage
Positive Sentiment: Upgrades and positive analyst notes (e.g., Zacks upgrade to Strong Buy and reaffirmations from boutique shops) have increased investor interest and buying pressure. Analyst coverage summary
Neutral Sentiment: Citigroup initiated coverage with a “neutral”/hold rating and a $62 price target (roughly single‑digit upside vs. current levels). That provides formal coverage but not a buy endorsement. Citigroup initiation
Neutral Sentiment: Media discussion about whether it’s “too late” after a ~234.5% rally is drawing attention — this can attract momentum traders but also encourages re‑rating/valuation debate among longer‑term investors. Yahoo Finance article
Negative Sentiment: CEO Jack Bendheim has sold multiple blocks of shares recently (most recently 7,040 shares at ~$54.64 on Apr 16). While the trades were executed under a pre‑arranged Rule 10b5‑1 plan (which limits informational inference), repeated insider sales can create short‑term caution among investors. InsiderTrades report

Wall Street Analyst Weigh In

A number of equities analysts recently commented on PAHC shares. Citigroup started coverage on Phibro Animal Health in a research note on Wednesday. They issued a “neutral” rating and a $62.00 price objective on the stock. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Morgan Stanley set a $49.00 price objective on Phibro Animal Health in a research note on Friday, February 6th. Finally, Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Phibro Animal Health presently has an average rating of “Hold” and a consensus target price of $42.40.

Check Out Our Latest Stock Report on Phibro Animal Health

About Phibro Animal Health

(Get Free Report)

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.